Centre for Epidemiological Modelling and Analysis (CEMA), have released results of three studies that could significantly ...

Experts have proposed new treatment modes for older people with HIV. The new treatment does not cause the health-threatening side effects found in the existing drugs. Experts at the ongoing ...

KUCHING: Asean member states must work together to reduce the cost of next-generation antiretroviral (ARV) drugs for HIV ...

ViiV Healthcare, the HIV-focused joint venture majority owned by GSK , said on Monday it has expanded its licensing deal with ...

Experts reveal that the new TLD treatment for HIV shows superior effectiveness and fewer side effects compared to the older TLE regimen, making it a significant advancement in HIV care ahead of ...

KUCHING: Asean must work together to reduce the cost of next-generation antiretroviral (ARV) drugs for HIV patients in their respective countries, says Datuk Lukanisman Awang Sauni.

Findings from Kenya by CEMA at the International AIDS Society Conference on HIV ScienceRwanda, July 15, 2025-- The University of Nairobi, Center for Epidemiological Modelling and Analysis (CEMA), has ...

The Global Fund announced Wednesday a deal with generic pharmaceutical manufacturers to significantly slash the price of a cutting-edge HIV drug, in a move it said would save lives.

Gilead Sciences Inc. said federal regulators had placed on hold trials of a new experimental once-weekly HIV drug combination therapy after white blood cell counts dropped in some of the patients.

Such a combination could potentially become a popular choice of therapy for the treatment-experienced population because of atazanavir's good safety profile and once-daily dosing.

SAN FRANCISCO — Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, baseline suppressive therapies among adults with HIV.

Researchers confirmed the dosing of an ART combination designed to treat children with HIV and found that it was safe, well tolerated and efficacious through 24 weeks, according to results ...